Abivax (ABVX) EBT (2022 - 2026)

Abivax's EBT history runs 5 years deep, the most recent figure standing at -$56.5 million for Q1 2026.

• On a quarterly basis, EBT fell 2.52% year-over-year to -$56.5 million in Q1 2026; TTM through Mar 2026 was -$379.2 million, a 90.06% decrease from a year earlier, with the FY2025 full-year figure at -$384.5 million, down 101.61% from the prior year.
• EBT grew to -$56.5 million in Q1 2026 per ABVX's latest filing, from -$88.7 million in the prior quarter.
• Across five years, EBT topped out at -$41.8 million in Q2 2024 and bottomed at -$179.3 million in Q3 2025.
• The 5-year median for EBT is -$56.5 million (2026), against an average of -$75.3 million.
• Across the five-year window, EBT jumped 69.33% in 2024 and slumped 195.6% in 2025, its largest moves.
• Year by year, EBT stood at -$66.1 million in 2022, then tumbled by 107.34% to -$137.1 million in 2023, then soared by 69.33% to -$42.0 million in 2024, then plunged by 110.9% to -$88.7 million in 2025, then soared by 36.29% to -$56.5 million in 2026.
• Per Business Quant, the three latest ABVX EBT figures stand at -$56.5 million (Q1 2026), -$88.7 million (Q4 2025), and -$179.3 million (Q3 2025).